Literature DB >> 15378205

New insight on the molecular mechanisms of high-density lipoprotein cellular interactions.

L O Martinez1, S Jacquet, F Tercé, X Collet, B Perret, R Barbaras.   

Abstract

High-density lipoprotein (HDL) cholesterol is an independent negative risk factor for coronary artery disease and thus represents today the only protective factor against atherosclerosis. The protective effect of HDL is mostly attributed to its central function in reverse cholesterol transport (RCT), a process whereby excess cell cholesterol is taken up and processed in HDL particles, and is later delivered to the liver for further metabolism and bile excretion. This process relies on specific interactions between HDL particles and cells, both peripheral (cholesterol efflux) and hepatic (cholesterol disposal) cells, and on the maturation of HDL particles within the vascular compartment. The plasma level of HDL cholesterol will thus result also from the complex interplay with cellular partners. Among them, some contribute to HDL formation - for instance ATP binding cassette AI protein - while others are mostly involved in HDL catabolism, the scavenger receptor-class B type I or the recently described membrane-bound ATP synthase/hydrolase. The last decade has seen major breakthroughs in the identification and elucidation of the role of cellular partners of HDL metabolism, and in their transcriptional regulations, opening up new perspectives in the modulation of HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378205     DOI: 10.1007/s00018-004-4087-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  20 in total

1.  Guidelines on management (diagnosis and treatment) of syncope.

Authors:  M Brignole; P Alboni; D Benditt; L Bergfeldt; J J Blanc; P E Bloch Thomsen; J G van Dijk; A Fitzpatrick; S Hohnloser; J Janousek; W Kapoor; R A Kenny; P Kulakowski; A Moya; A Raviele; R Sutton; G Theodorakis; W Wieling
Journal:  Eur Heart J       Date:  2001-08       Impact factor: 29.983

Review 2.  Postural tachycardia syndrome (POTS).

Authors:  Satish R Raj
Journal:  Circulation       Date:  2013-06-11       Impact factor: 29.690

Review 3.  Syncope: classification and risk stratification.

Authors:  Venkata Krishna Puppala; Oana Dickinson; David G Benditt
Journal:  J Cardiol       Date:  2014-01-07       Impact factor: 3.159

4.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome.

Authors:  Roy Freeman; Wouter Wieling; Felicia B Axelrod; David G Benditt; Eduardo Benarroch; Italo Biaggioni; William P Cheshire; Thomas Chelimsky; Pietro Cortelli; Christopher H Gibbons; David S Goldstein; Roger Hainsworth; Max J Hilz; Giris Jacob; Horacio Kaufmann; Jens Jordan; Lewis A Lipsitz; Benjamin D Levine; Phillip A Low; Christopher Mathias; Satish R Raj; David Robertson; Paola Sandroni; Irwin Schatz; Ron Schondorff; Julian M Stewart; J Gert van Dijk
Journal:  Clin Auton Res       Date:  2011-04       Impact factor: 4.435

5.  Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial).

Authors:  Nynke van Dijk; Fabio Quartieri; Jean-Jaques Blanc; Roberto Garcia-Civera; Michele Brignole; Angel Moya; Wouter Wieling
Journal:  J Am Coll Cardiol       Date:  2006-09-26       Impact factor: 24.094

Review 6.  Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology.

Authors: 
Journal:  Neurology       Date:  1996-05       Impact factor: 9.910

Review 7.  Incidence, etiology and predictors of adverse outcomes in 43,315 patients presenting to the Emergency Department with syncope: an international meta-analysis.

Authors:  Fabrizio D'Ascenzo; Giuseppe Biondi-Zoccai; Matthew J Reed; Gelareh Z Gabayan; Masaru Suzuki; Giorgio Costantino; Raffaello Furlan; Andrea Del Rosso; Francois P Sarasin; Benjamin C Sun; Maria Grazia Modena; Fiorenzo Gaita
Journal:  Int J Cardiol       Date:  2011-12-20       Impact factor: 4.164

8.  The relationship between health-related quality of life and frequency of spells in patients with syncope.

Authors:  M S Rose; M L Koshman; S Spreng; R Sheldon
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

9.  Role of autonomic reflexes in syncope associated with paroxysmal atrial fibrillation.

Authors:  M Brignole; L Gianfranchi; C Menozzi; A Raviele; D Oddone; G Lolli; N Bottoni
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

10.  Role of early symptoms in assessment of syncope in elderly people: results from the Italian group for the study of syncope in the elderly.

Authors:  Galizia Galizia; Pasquale Abete; Chiara Mussi; Gabriele Noro; Alessandro Morrione; Assunta Langellotto; Annalisa Landi; Francesco Cacciatore; Giulio Masotti; Franco Rengo; Niccolò Marchionni; Andrea Ungar
Journal:  J Am Geriatr Soc       Date:  2008-11-20       Impact factor: 5.562

View more
  10 in total

1.  Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes.

Authors:  A C S Fabre; P Vantourout; E Champagne; F Tercé; C Rolland; B Perret; X Collet; R Barbaras; L O Martinez
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

Review 2.  Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity.

Authors:  Eric Champagne; Laurent O Martinez; Pierre Vantourout; Xavier Collet; Ronald Barbaras
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance.

Authors:  Dan Liao; Hongmei Tan; Rutai Hui; Zhaohui Li; Xiaohua Jiang; John Gaubatz; Fan Yang; William Durante; Lawrence Chan; Andrew I Schafer; Henry J Pownall; Xiaofeng Yang; Hong Wang
Journal:  Circ Res       Date:  2006-08-24       Impact factor: 17.367

4.  An induction in hepatic HDL secretion associated with reduced ATPase expression.

Authors:  Nihar R Pandey; Joanna Renwick; Seham Rabaa; Ayesha Misquith; Lara Kouri; Erin Twomey; Daniel L Sparks
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

5.  Apolipoprotein AI tertiary structures determine stability and phospholipid-binding activity of discoidal high-density lipoprotein particles of different sizes.

Authors:  Bin Chen; Xuefeng Ren; Tracey Neville; W Gray Jerome; David W Hoyt; Daniel Sparks; Gang Ren; Jianjun Wang
Journal:  Protein Sci       Date:  2009-05       Impact factor: 6.725

6.  Oxidative markers, nitric oxide and homocysteine alteration in hypercholesterolimic rats: role of atorvastatine and cinnamon.

Authors:  Kamal A Amin; Thanaa M Abd El-Twab
Journal:  Int J Clin Exp Med       Date:  2009-10-05

7.  P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivo.

Authors:  Marine Goffinet; Claudine Tardy; Nadia Boubekeur; Guy Cholez; Alice Bluteau; Daniela C Oniciu; Narendra D Lalwani; Jean-Louis H Dasseux; Ronald Barbaras; Rudi Baron
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

8.  Hypolipidemic and antioxidative effects of aqueous enzymatic extract from rice bran in rats fed a high-fat and -cholesterol diet.

Authors:  Yu-Xin Wang; Yang Li; An-Min Sun; Feng-Jiao Wang; Guo-Ping Yu
Journal:  Nutrients       Date:  2014-09-16       Impact factor: 5.717

Review 9.  Lipid Metabolic Process Involved in Oocyte Maturation During Folliculogenesis.

Authors:  Tao Liu; Jiangxue Qu; Mengyuan Tian; Rui Yang; Xueling Song; Rong Li; Jie Yan; Jie Qiao
Journal:  Front Cell Dev Biol       Date:  2022-03-31

10.  Pharmacological Screening of Trachyspermum ammi for Antihyperlipidemic Activity in Triton X-100 Induced Hyperlipidemia Rat Model.

Authors:  Uzma Saleem; Saba Riaz; Bashir Ahmad; Mohammad Saleem
Journal:  Pharmacognosy Res       Date:  2017-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.